Literature DB >> 11840413

Surgical management of ovarian cancer.

David G Mutch1.   

Abstract

The management of ovarian cancer presents one of the greatest challenges to physicians caring for patients with cancer. The treatment almost always involves a combination of surgery and chemotherapy. Over the past 75 years we have formed a rational system for the surgical management of this disease. Initial surgical therapy should include the following three objectives: (1) staging, (2) cytoreduction, and (3) determining a definitive histologic diagnosis. The importance of meticulous staging cannot be overstated. Fully one third of patients not compulsively staged will be upstaged if surgically restaged. Cytoreductive surgery is the mainstay of initial treatment. Data clearly demonstrate that ovarian cancer is different from other solid tumors in that reduction of the tumor burden is important in the management of this disease. Patients with less than 1 to 2 cm of disease remaining at the conclusion of initial surgery have a survival advantage over those who do not. The benefits of secondary cytoreduction are less clear, and data support the concept of cytoreduction in many circumstances. These surgical issues surrounding ovarian cancer support the concept that physicians trained to treat ovarian cancer be involved in its management. Data are emerging that clearly suggest that gynecologic oncologists should be involved in both the surgical and medical management of patients with ovarian cancer. Copyright 2002 by W.B. Saunders Company.

Entities:  

Mesh:

Year:  2002        PMID: 11840413     DOI: 10.1053/sonc.2002.31589

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  16 in total

Review 1.  Platelet effects on ovarian cancer.

Authors:  Ashley N Davis; Vahid Afshar-Kharghan; Anil K Sood
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

2.  A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.

Authors:  Hsin-Yao Tang; Lynn A Beer; Tony Chang-Wong; Rachel Hammond; Phyllis Gimotty; George Coukos; David W Speicher
Journal:  J Proteome Res       Date:  2011-11-18       Impact factor: 4.466

3.  Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence.

Authors:  Madhumita Chatterjee; Greg Dyson; Nancy K Levin; Jay P Shah; Robert Morris; Adnan Munkarah; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2012       Impact factor: 4.388

Review 4.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 5.  Development and validation of a protein-based signature for the detection of ovarian cancer.

Authors:  Kyongjin Kim; Irene Visintin; Ayesha B Alvero; Gil Mor
Journal:  Clin Lab Med       Date:  2009-03       Impact factor: 1.935

6.  Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.

Authors:  Hsin-Yao Tang; Lynn A Beer; Janos L Tanyi; Rugang Zhang; Qin Liu; David W Speicher
Journal:  J Proteomics       Date:  2013-06-21       Impact factor: 4.044

7.  Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential.

Authors:  G Yin; A B Alvero; V Craveiro; J C Holmberg; H-H Fu; M K Montagna; Y Yang; I Chefetz-Menaker; S Nuti; M Rossi; D-A Silasi; T Rutherford; G Mor
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

8.  Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.

Authors:  Rohini Sharma; Janet Graham; Sarah Blagden; Hani Gabra
Journal:  BMC Cancer       Date:  2011-07-11       Impact factor: 4.430

9.  Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.

Authors:  Mihaela Campan; Melissa Moffitt; Sahar Houshdaran; Hui Shen; Martin Widschwendter; Günter Daxenbichler; Tiffany Long; Christian Marth; Ite A Laird-Offringa; Michael F Press; Louis Dubeau; Kimberly D Siegmund; Anna H Wu; Susan Groshen; Uma Chandavarkar; Lynda D Roman; Andrew Berchuck; Celeste L Pearce; Peter W Laird
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

10.  KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Authors:  Ki Hyung Kim; Yanhua Xie; Ewan M Tytler; Richard Woessner; Gil Mor; Ayesha B Alvero
Journal:  J Transl Med       Date:  2009-07-20       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.